Christie Hilton, DO
Hematology & Oncology · New Castle, PANPI 1700115763
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AstraZeneca at 44.8% of the total.
Across 92 payments — averaging $310.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Gilead$9K
- Daiichi Sankyo Inc.$3K
- Tolmar, Inc.$2K
- Novartis$763
- Genentech USA, Inc.$400
- plus $768 from 8 others
Across 51 payments — averaging $4556.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$135K
- Genentech, Inc.$25K
- F. Hoffmann-la Roche AG$20K
- Merck$17K
- Eli Lilly$17K
- Immunomedics, Inc.$13K
- plus $6K from 1 others
What the payments were for
- Consulting fees$15,52854%
- Speaking & faculty fees$9,63334%
- Travel & lodging$9373%
- Food & beverage$1,6056%
- Education$1220%
- Other$7163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $12,795 |
| Gilead | 10 | $9,249 |
| Daiichi Sankyo Inc. | 3 | $2,765 |
| Tolmar, Inc. | 1 | $1,800 |
| Novartis | 10 | $763 |
| Genentech USA, Inc. | 42 | $400 |
| E.r. Squibb & Sons, L.L.C. | 5 | $302 |
| Puma Biotechnology, Inc. | 2 | $133 |
| Astellas Pharma US Inc | 1 | $95 |
| Array Biopharma Inc | 1 | $91 |
| Tactile Systems Technology Inc | 1 | $83 |
| Seagen Inc. | 1 | $28 |
| Bristol Myers Squibb | 1 | $23 |
| Tempus AI, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,540 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 50 | $734,034 |
| IbrancePalbociclib | 23 | $325,786 |
| Anastrozole | 85 | $1,392 |
| Prochlorperazine Maleate | 34 | $321 |
| Letrozole | 14 | $308 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Castle
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.